Chronic Kidney Disease in India

Although, chronic kidney disease (CKD) is a global issue, but its impact on countries like India is particularly significant. Let’s dive into the key challenges:

High Prevalence of Chronic Kidney Disease in India

India faces a growing epidemic of kidney disease. Around 10% of the world’s population is affected by CKD, and millions die each year because of limited access to affordable treatment.

Visual representation of the geographic burden of kidney disease in the world looks something like this –

Territories are sized in proportion to the absolute number of people who died from kidney disease in 1 year. Copyright: SASI Group (University of Sheffield) and Mark Newman (University of Michigan).

India, with the highest incidences of diabetes and Hypertension in the world, is likely to face a catastrophic kidney disease(CKD)/ESRD burden, with 25–40% of its population at risk

The rising numbers are alarming, making CKD a major public health concern.

Impact on Developing Nations Including India

In the global context, CKD has been steadily climbing the ranks in terms of mortality. According to the Global Burden of Disease study, CKD went from being the 27th cause of total deaths worldwide in 1990 to the 18th in 2010. This increase in mortality is a significant concern, especially when you consider the impact on developing countries and affordability of treatments for kidney disease.

Lack of Access to Treatment of Kidney Disease

Over two million people worldwide currently receive treatment with dialysis or a kidney transplant. However, this number represents only a fraction (~10%) of those who need treatment to survive.

  • Of this 2 million people who receive treatment for kidney failure, the majority are treated in only five countries – the United States, Japan, Germany, Brazil, and Italy. These five countries represent only 12% of the world population.
  • Only 20% are treated in about 100 developing countries that make up over 50% of the world population.
  • More than 80% of all patients who receive treatment for kidney failure are in affluent
    countries with universal access to health care
     and large elderly populations.

Treatment for kidney failure is often concentrated in a few high-income countries, leaving many low- and middle-income nations (such as India) struggling to provide adequate care.

Financial Burden & Affordability of Treatments for Kidney Disease

CKD poses a massive financial burden on individuals and healthcare systems.

  • For instance, the cost of treating CKD in the US is estimated to exceed $48 billion annually.
  • In China, the economy will lose US$558 billion over the next decade due to effects on death and disability attributable to heart disease and kidney disease.
  • It is estimated that number of cases of chronic kidney disease and failure will increase disproportionately in developing countries, such as China and India, where the number of elderly people are increasing. In middle-income countries, treatment with dialysis or kidney transplantation creates a huge financial burden for the majority of the people who need it. In another 112 countries, many people cannot afford treatment at all, resulting in the death of over 1 million people annually from untreated kidney failure.

Treatment for kidney failure consumes a substantial portion of healthcare budgets, despite a small percentage of the population requiring it.

Affordable & holistic therapies for chronic kidney disease

68 naturopathic interventions spanning over 14 amazing chapters, supported by hundreds of medical studies published in journals of medicine, biochemistry and nephrology, to improve kidney’s health


Connection to Hypertension and Diabetes Throughout the World and Asia/India

The increase in kidney disease cases is closely linked to the global rise in diabetes and hypertension, both of which are prevalent in India.

  • Over 5% of people with newly diagnosed type 2 diabetes already have chronic kidney disease (CKD). An estimated 40% of both type 1 and type 2 diabetics will develop CKD during their lifetimes, with the majority developing CKD within 10 years of diagnosis.
  • About 45% of patients with end-stage kidney disease (ESKD/ESRD) in most developed countries have diabetes.
  • The prevalence of type 2 diabetes has almost doubled in the United States and has increased three- to fivefold in India, Indonesia, China, Korea, and Thailand.
  • The Demand Project tested diabetics across various countries and found that nearly half had microalbuminuria, a key CKD marker.

The coexistence of these conditions exacerbates the CKD problem in India.

Taking Back Control – Affordable & Alternate Therapies for Kidney Disease in India

As I delved deeper into my own health journey and researched CKD in India, I realized the critical need for individuals to take control of their health. Modern medicine, while essential, often falls short in treating chronic degenerative diseases like CKD. Many medications meant for lifestyle diseases have their own side effects and can contribute to nephrotoxicity, a condition where drugs harm the kidneys.

We need to shift our focus from relying solely on pharmaceutical treatments and embrace holistic and affordable approaches grounded in science and biochemistry. This includes exploring non-toxic therapies, natural remedies, dietary changes, and lifestyle adjustments that can promote kidney health and combat aging.

References

  • World Kidney Day: Chronic Kidney Disease. 2015; http://www.worldkidneyday.org/faqs/chronic-kidney-disease/
  • National Kidney Foundation. (2015, March 11). Global facts: About kidney diseasehttps://www.kidney.org/kidneydisease/global-facts-about-kidney-disease#:
  • Couser WG, Remuzzi G, Mendis S, Tonelli M. The contribution of chronic kidney disease to the global burden of major noncommunicable diseases. Kidney Int. Dec 2011;80(12):1258-1270.
  • Jha V, Garcia-Garcia G, Iseki K, et al. Chronic kidney disease: global dimension and perspectives. Lancet. Jul 20 2013;382(9888):260-272.
  • Srinath Reddy K, Shah B, Varghese C, Ramadoss A. Responding to the threat of chronic diseases in India. Lancet. 2005 Nov 12;366(9498):1744-9. doi: 10.1016/S0140-6736(05)67343-6. PMID: 16291069.

Leave a Comment

Your email address will not be published. Required fields are marked *

Shopping Cart